Scancell Holdings
plc
("Scancell" or the "Company")
Issue of share
options
Scancell Holdings plc (AIM: SCLP), a
clinical-stage biopharmaceutical company developing novel
immunotherapies for cancer, announces that on 19 February 2025,
share options to acquire ordinary shares of 0.1 pence each in the
capital of the Company (the "Options") were granted to Phil
L'Huillier, CEO and Executive Director, Lindy Durrant, CSO and
Executive Director and Sath Nirmalananthan, CFO and Executive
Director (the "Executive Directors").
The Options have been granted as
follows:
|
Director
|
Existing options over
Ordinary Shares
|
Number of Options
granted
|
Total options held following
grant
|
% of current issued share
capital
|
|
Phil L'Huillier
|
0
|
31,103,440
|
31,103,440
|
3.00%
|
|
Lindy Durrant
|
22,850,000
|
5,183,907
|
28,033,907
|
2.70%
|
|
Sath Nirmalananthan
|
1,000,000
|
1,000,000
|
2,000,000
|
0.19%
|
The Options have been granted pursuant to the
Company's long term incentive plan, have an exercise price of
11.7 pence each, the 3 month volume weighted average price on
the grant date, and will vest over three years in three equal
tranches from 19 February 2025 with no vesting criteria other than
to remain in employment. Any unexercised Options which are being
granted per the above will expire at 6pm on 19 February
2035.
The Board of Scancell approved the issuance of
the Options to incentivise and retain directors and staff of the
Company. The Board considered both historical practices and
on-going funding requirements in this regard.
Related Party
Transaction
The issue of Options to the Executive Directors
are deemed to be a related party transaction pursuant to AIM Rule
13 of the AIM Rules for Companies. The Company's directors who are
independent of the related party transaction, being all the
directors other than the Executive Directors, consider, having
consulted with the Company's Nominated Adviser, Panmure Liberum
Limited, that the terms of the related party transactions are fair
and reasonable insofar as the shareholders of the Company are
concerned.
NOTIFICATION AND PUBLIC DISCLOSURE OF
TRANSACTIONS BY PERSONS DISCHARGING
MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY
ASSOCIATED WITH THEM
|
1
|
Details of the person discharging managerial
responsibilities/person closely associated
|
|
a)
|
Name
|
Phil L'Huillier
|
|
2
|
Reason for the notification
|
|
a)
|
Position/status
|
Chief Executive Officer and PDMR
|
|
b)
|
Initial notification/Amendment
|
Initial notification
|
|
3
|
Details of the issuer, emission allowance
market participant, auction platform, auctioneer or auction
monitor
|
|
a)
|
Name
|
Scancell Holdings plc
|
|
b)
|
LEI
|
2138008RXEG856SNP666
|
|
4
|
Details of the transaction(s): section to be
repeated for (i) each type of instrument; (ii) each type of
transaction; (iii) each date; and (iv) each place where
transactions have been conducted
|
|
a)
|
Description of the financial instrument, type
of instrument
|
Options to acquire ordinary shares
|
|
b)
|
Identification Code
|
GB00B63D3314
|
|
c)
|
Nature of the transaction
|
Grant of options to acquire ordinary
shares
|
|
|
|
|
|
d)
|
Price(s) and volume(s)
|
31,103,440 share options
11.7 pence per share option
|
|
e)
|
Aggregated information
- Aggregated volume
- Price
|
N/A (single transaction)
|
|
f)
|
Date of the transaction
|
19 February 2025
|
|
g)
|
Place of the transaction
|
Outside a trading venue
|
|
1
|
Details of the person discharging managerial
responsibilities/person closely associated
|
|
a)
|
Name
|
Lindy Durrant
|
|
2
|
Reason for the notification
|
|
a)
|
Position/status
|
Chief Scientific Officer and PDMR
|
|
b)
|
Initial notification/Amendment
|
Initial notification
|
|
3
|
Details of the issuer, emission allowance
market participant, auction platform, auctioneer or auction
monitor
|
|
a)
|
Name
|
Scancell Holdings plc
|
|
b)
|
LEI
|
2138008RXEG856SNP666
|
|
4
|
Details of the transaction(s): section to be
repeated for (i) each type of instrument; (ii) each type of
transaction; (iii) each date; and (iv) each place where
transactions have been conducted
|
|
a)
|
Description of the financial instrument, type
of instrument
|
Options to acquire ordinary shares
|
|
b)
|
Identification Code
|
GB00B63D3314
|
|
c)
|
Nature of the transaction
|
Grant of options to acquire ordinary
shares
|
|
|
|
|
|
d)
|
Price(s) and volume(s)
|
5,183,907 share options
11.7 pence per share option
|
|
e)
|
Aggregated information
- Aggregated volume
- Price
|
N/A (single transaction)
|
|
f)
|
Date of the transaction
|
19 February 2025
|
|
g)
|
Place of the transaction
|
Outside a trading venue
|
|
1
|
Details of the person discharging managerial
responsibilities/person closely associated
|
|
a)
|
Name
|
Sath Nirmalananthan
|
|
2
|
Reason for the notification
|
|
a)
|
Position/status
|
Chief Financial Officer and PDMR
|
|
b)
|
Initial notification/Amendment
|
Initial notification
|
|
3
|
Details of the issuer, emission allowance
market participant, auction platform, auctioneer or auction
monitor
|
|
a)
|
Name
|
Scancell Holdings plc
|
|
b)
|
LEI
|
2138008RXEG856SNP666
|
|
4
|
Details of the transaction(s): section to be
repeated for (i) each type of instrument; (ii) each type of
transaction; (iii) each date; and (iv) each place where
transactions have been conducted
|
|
a)
|
Description of the financial instrument, type
of instrument
|
Options to acquire ordinary shares
|
|
b)
|
Identification Code
|
GB00B63D3314
|
|
c)
|
Nature of the transaction
|
Grant of options to acquire ordinary
shares
|
|
|
|
|
|
d)
|
Price(s) and volume(s)
|
1,000,000 share options
11.7 pence per share option
|
|
e)
|
Aggregated information
- Aggregated volume
- Price
|
N/A (single transaction)
|
|
f)
|
Date of the transaction
|
19 February 2025
|
|
g)
|
Place of the transaction
|
Outside a trading venue
|
-ENDS-
For
further information, please contact:
Scancell Holdings plc
+44 (0) 20 3709
5700
Phil L'Huillier, CEO
Sath Nirmalananthan, CFO
Professor Lindy Durrant,
CSO
Dr Jean-Michel Cosséry,
Non-Executive Chairman
Panmure Liberum Limited (Nominated Advisor and Joint
Broker)
+44
(0) 20 7886 2500
Emma Earl/ Will Goode/ Mark Rogers
(Corporate Finance)
Rupert Dearden (Corporate
Broking)
WG
Partners LLP (Joint Broker)
+44
(0) 20 3705 9330
David Wilson/ Claes Spang/ Satheesh
Nadarajah/ Erland Sternby
ICR
Healthcare
+44
(0) 20 37095700
Mary-Jane Elliott/ Angela Gray/
Stephanie Cuthbert
scancell@icrhealthcare.com
About Scancell
Scancell is a clinical stage
biopharmaceutical company that is leveraging its proprietary
research, built up over many years of studying the human adaptive
immune system, to generate novel medicines to treat significant
unmet needs in cancer. The Company is building a pipeline of
innovative products by utilising its four technology platforms:
Moditope® and ImmunoBody® for vaccines and GlyMab® and AvidiMab®
for antibodies. Adaptive immune responses include
antibodies and T cells (CD4 and CD8), both of which can recognise
damaged or infected cells. In order to destroy such cancerous or
infected cells, Scancell uses either vaccines to induce immune
responses or monoclonal antibodies (mAbs) to redirect immune cells
or drugs. The Company's unique approach is that its innovative
products target modifications of proteins and lipids. For the
vaccines (Moditope® and ImmunoBody® ) this includes citrullination
and homocitrullination of proteins, whereas its mAb portfolio
targets glycans or sugars that are added onto proteins and / or
lipids (GlyMab® ) or enhances the potency of antibodies and their
ability to directly kill tumour cells (AvidiMab®
).
For further information about
Scancell, please visit: https://www.scancell.co.uk/
